Dr. Michael Yassa
Claim this profileMaisonneuve-Rosemont Hospital
Studies Breast Cancer
Studies Postmastectomy Lymphedema Syndrome
6 reported clinical trials
8 drugs studied
Area of expertise
1Breast Cancer
Stage I
Stage II
HER2 negative
2Postmastectomy Lymphedema Syndrome
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Michael Yassa is currently running
Short-Course Radiation Therapy
for Breast Cancer
Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalent to longer fractionation schedules in the upfront treatment setting. These 1-week schedules are more convenient for patients, with fewer treatments and shorter overall treatment time. The investigators hypothesize that a 1-week ultra-hypofractionated rPBI regimen following breast-conserving surgery (BCS) for local recurrence or new primary breast cancer in the previously irradiated breast (LR) will be associated with acceptable toxicity at 1 year (\<13% grade \>3 toxicity).
Recruiting1 award N/A8 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
More about Michael Yassa
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Michael Yassa has experience with
- Single Pre-Operative Radiation Therapy
- Locoregional Radiation Treatment
- RPBI
- Regional Nodal XRT
- Chestwall XRT
- WBI
Breakdown of trials Michael Yassa has run
Breast Cancer
Postmastectomy Lymphedema Syndrome
Radiotherapy
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Yassa specialize in?
Michael Yassa focuses on Breast Cancer and Postmastectomy Lymphedema Syndrome. In particular, much of their work with Breast Cancer has involved Stage I patients, or patients who are Stage II.
Is Michael Yassa currently recruiting for clinical trials?
Yes, Michael Yassa is currently recruiting for 3 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Michael Yassa has studied deeply?
Yes, Michael Yassa has studied treatments such as Single Pre-Operative Radiation Therapy, Locoregional radiation treatment, rPBI.
What is the best way to schedule an appointment with Michael Yassa?
Apply for one of the trials that Michael Yassa is conducting.
What is the office address of Michael Yassa?
The office of Michael Yassa is located at: Maisonneuve-Rosemont Hospital, Montreal, Quebec H1T 2M4 Canada. This is the address for their practice at the Maisonneuve-Rosemont Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.